Zymeworks strikes $929 million deal for Theravance Biopharma
Zymeworks strikes $929 million deal for Theravance Biopharma June 29 (Reuters) - Drugmaker Zymeworks ZYME.O said on Monday it will buy Theravance Biopharma TBPH.O in a $929 million deal.
(Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Jonathan Ananda)
Recent news on Theravance Biopharma
See all newsTheravance Biopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary
Ireland's Theravance Biopharma Q2 revenue rises 11% but misses estimates
Brief: Theravance Biopharma Q2 Operating Income USD -8.277 Million
Press Digest: Canada - June 30
Deals of the day-Mergers and acquisitions